Cargando…
C9orf16 represents the aberrant genetic programs and drives the progression of PDAC
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), constituting 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Lack of early detection of PDAC contributes to its poor prognosis as patients are often diagnosed at an advanced stage of disease. This is m...
Autores principales: | Chen, Xiaojun, Zhang, Hong, Xiao, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615161/ https://www.ncbi.nlm.nih.gov/pubmed/36307773 http://dx.doi.org/10.1186/s12885-022-10202-5 |
Ejemplares similares
-
SMAD4 Y353C promotes the progression of PDAC
por: Wang, Zusen, et al.
Publicado: (2019) -
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020) -
ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014) -
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021) -
C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation
por: Ozawa, Tatsuya, et al.
Publicado: (2021)